This post was originally published on this site Stereotactic body radiotherapy (SBRT), which delivers higher doses of radiation over a significantly shorter period of time, can be safely given to men with low- or intermediate-risk prostate cancer with similar long-term efficacy as conventional radiation therapy, a study shows. The approach, which reduces the duration of treatment…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC
This post was originally published on this site Adding Celsion‘s GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during surgery, without causing significant side effects, a Phase 1b trial shows. The trial’s data were presented at the…
NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers
This post was originally published on this site NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation antigen, or BCMA. The therapy, called chimeric antigen receptor (CAR) NK-cell, is a tweaked version of the conventional CAR-T cell therapy: instead of isolating…
Unusual Case Cites Infection as Possible Trigger of Sarcoidosis
This post was originally published on this site A study reporting the case of a sarcoidosis patient infected with the bacteria Borrelia burgdorferi highlights the importance of maintaining an increased awareness about potential infectious conditions, such as Lyme disease, in patients with new onset of sarcoidosis. The case study, “Systemic Sarcoidosis Associated with Exposure to Borrelia burgdorferi…
Vitamin C Might Reverse Stress-induced Driver of Breast Cancer, Study Says
This post was originally published on this site Chronic stress and the consequent release of the stress hormone epinephrine may help breast cancer cells grow by helping them get more energy, a study in mice shows. This effect might be reversed through treatment with vitamin C, researchers report. The study, “Stress-induced epinephrine enhances lactate dehydrogenase A…
FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC
This post was originally published on this site The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the first immunotherapy regimen approved specifically for breast cancer. The approval, which is for patients whose tumors produce…
Ultrasensitive Chip Detects Cancer Faster, Less Invasively than Current Approaches, Study Suggests
This post was originally published on this site Researchers have developed an ultrasensitive diagnostic device, a kind of “lab-on-a-chip,” that quickly detects cancer using a droplet of blood, potentially allowing for an easier, cheaper, and more timely cancer diagnosis. The device is described in the study, “Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip,”…
Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma
This post was originally published on this site A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma, may also be effective and safe as a first-line treatment for newly diagnosed patients, according to a study. The dual combo yielded the highest response rates to date for a two-agent combination employed as…
Brexit Could Have Real Effects for UK Rare Disease Patients, Experts Warn
This post was originally published on this site Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term…
Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage
This post was originally published on this site The expansion stage of a Phase 1/2 trial testing tinostamustine in relapsed or refractory types of lymphoma and other blood cancers has enrolled a first patient. The study (NCT02576496) is currently enrolling up to 65 patients in the U.S. and Europe with advanced multiple myeloma, Hodgkin’s lymphoma, peripheral T-cell…
TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy
This post was originally published on this site TC BioPharm (TCB) and Trinity College Dublin researchers are working together to expedite the production of V delta 1 γδ T cells to be used in the fight against solid tumors. TCB’s in-house Good Manufacturing Practice (GMP) team will be working with Derek Doherty, an associate professor and head of immunology…
Provenge Better for African-Americans Than Men of Other Ethnicities, Analysis Shows
This post was originally published on this site Provenge (sipuleucel-T), a treatment approved in the U.S. for metastatic castration-resistant prostate cancer, significantly increased the number of patients alive at three years, compared to a placebo, a retrospective analysis of Phase 3 clinical data shows. The treatment, which harnesses the immune system to fight cancer, was…